YD Bio Limited Warrants

YD Bio announced that its affiliate EG BioMed US obtained out-of-state clinical laboratory licenses in Rhode Island and Pennsylvania, expanding its CLIA-certified laboratory's authorized operating footprint to 46 U.S. states plus Washington D.C. and Guam. The expansion supports the company's DNA methylation-based early cancer detection operations...

YD Bio (Nasdaq: YDES) announced full-year 2025 financial results showing 17% net revenue increase to $596.8 million, driven by pharmaceutical sales growth and new product launches. However, the company reported a net loss of $8.3 million compared to $1.4 million in 2024, primarily due to a $3.2 million change in warrant liabilities and increased ...

YD Bio Limited plans to establish a new U.S. operations center in California to accelerate clinical development, regulatory engagement, and commercial access for cancer diagnostics and exosome-based therapeutics.